Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Post by bball67on Jul 11, 2023 12:45pm
212 Views
Post# 35535677

Conjecture

Conjecture I don't know what's going on with Promis. My Investor relations guy is silent. Believe the Company is silent based on no response to my request to speak with Gail. The natural buyers like insiders and the Boston Group appear not to be active. Believe the consolidation is not so much about cost savings but rather one less regulator going forward. So, without natural buyers at half the price, the stock is 50% of $6. I was told back in February that the likely finanancing would happen at the end of phase 1a to eliminate any possible issues. It is probably completed in my opinion. Don't think we are going to get a financing because the Boston Group would be supporting the stock. My guess is that there is a possibility of a sale of the Company or a partnership deal and that the elimination of the Canadian listing was part of the process. There are a lot of clues. This is my conjecture. Bought 4000 shares in last few days. Believe a minimal valuation is $100-200M. 
<< Previous
Bullboard Posts
Next >>